Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743690 | 1.00 | KIF11 (0.60) | KIF11MAOBTAAR1PRSS1ACR | |
| SCHEMBL3739838 | 0.86 | KIF11 (0.49) | KIF11MAOBTAAR1PRSS1ACR | |
| SCHEMBL3741169 | 0.85 | KMT2A (0.54) | KIF11MAOBTAAR1LTA4HEPHX2 | |
| SCHEMBL3729914 | 0.83 | MAOB (0.55) | MAOBTAAR1EPHX2CYP1A1CYP1B1 | |
| SCHEMBL3733475 | 0.83 | KIF11 (0.43) | KIF11MAOBTAAR1ALDH1A1NR3C2 | |
| SCHEMBL3736072 | 0.82 | KIF11 (0.42) | KIF11MAOB | |
| SCHEMBL3734740 | 0.82 | TAAR1 (0.43) | MAOBTAAR1ALDH1A1CYP1A2 | |
| SCHEMBL4316832 | 0.81 | KIF11 (0.89) | KIF11MAOBPRSS1ACREPHX2 | |
| SCHEMBL3743140 | 0.80 | MMP1 (0.48) | ALDH1A1 | |
| SCHEMBL28909073 | 0.79 | KIF11 (0.86) | KIF11MAOBPRSS1ACREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | KIF11 4556/4885MAOB 716/4885TAAR1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.